

AMENDMENTS

Please cancel claims 104-106, and 125 without prejudice.

Please amend claim 103 as follows:

103. (Amended) An isolated, enriched or purified immunogenic composition comprising:

one or more autologous target carcinoma or lymphoma cells which are irradiated and treated in vitro wherein said target carcinoma or lymphoma cells express one or more primary or costimulatory T cell activation molecules at a level higher than the amount of primary or costimulatory T cell activation molecules expressed from carcinoma or lymphoma cells without treatment in a patient mammal;

one or more antibodies wherein said antibodies further bind to an antigenic binding site on the surface of said one or more target carcinoma or lymphoma cells;

one or more primary or costimulatory T cell activation molecules on the surface of T cells in said patient mammal; and

a bridge molecule binding said antibodies and said primary or costimulatory T cell activation molecules on the surface of T cells of said patient mammal.

Please add new claims 140-143 as follows:

--140. The composition of claim 103, wherein said target carcinoma cells further comprise hepatocellular carcinoma or colorectal carcinoma cells.

141. The composition of claim 103, wherein said antibodies further comprise one or more binding sites for antigen gp55.

142. The composition of claim 103, wherein said primary or costimulatory T cell activation molecules bind to CD28 or 4-1BB.

143. The composition of claim 103, wherein said bridge molecule further comprises
bispecific monoclonal antibody.--